Autoimmunity Flashcards

1
Q

3 ways autoimmunity can occur

A
  1. immune regulation dysfunction: loss of Treg activity
  2. normal self-antigens become modified by drugs, environmental chemicals, viruses, mutations
  3. molecular mimicry: exposure to antigen very similar to self antigen
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what are the 3 possible outcomes for immature lymphocytes that recognize self-antigen in central and peripheral tolerance, respectively?

A

central tolerance: either apoptosis, receptor editing (B cells), or development of Treg (T cells)

peripheral tolerance: either anergy, apoptosis, or suppression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

how does anergy of T cells occur?

A

when TCR binds MHC on DC, but there is no signal 2 (B7 on DC binds CD28 on T cell)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

natural vs induced Tregs

A

natural Tregs exist in the thymus already (most Tregs)

induced Tregs are a subset of immature T cells that recognized self-antigen, so are converted to Tregs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

_____ is a transcriptional activator that is turned on only in Tregs

A

Foxp3+

key marker of Tregs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Foxp3+

A

transcriptional activator turned on only in Tregs, key marker of Tregs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

you find a cell that expresses the following:
- CD4+
- IL-2 R
- IL-7 R
- Foxp3+
- GITR+

what kind of cell is it?

A

Treg

in particular, Foxp3+ is a key marker

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX)

A

caused by Foxp3+ mutation —> nonfunctional Treg cells

  • early onset T1 diabetes (insulin dependent)
  • watery diarrhea
  • failure to thrive - most affected children die within 2 years
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

mutation in Foxp3 causes what autoimmune disease

A

Foxp3 is critical transcriptional activator for Tregs

mutation —> IPEX
(immune dysregulation, polyendocrinopathy, enteropathy, X-linked)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

APC or APECED

A

APC = autoimmune polyglandular syndrome
APECED = autoimmune polyendocrinopathy candidiasis-ectodermal dystrophy

AR autoimmune disease
- yeast infections
- hypoparathyroidism
- Addison’s disease

mutation in AIRE gene (AutoImmune REgulator), which turns on expression of tissue-specific proteins in the thymus so immature T cells are exposed to them during negative selection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what occurs from a mutation in AIRE gene?

A

AIRE = AutoImmune REgulator

mutation —>

APC = autoimmune polyglandular syndrome
APECED = autoimmune polyendocrinopathy candidiasis-ectodermal dystrophy

AR autoimmune disease
- yeast infections
- hypoparathyroidism
- Addison’s disease

[remember that AIRE is responsible for turning on expression of tissue-specific proteins in thymus so immature T cells are exposed to them, and won’t react to them when they are released throughout the body]

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

how does negative selection of T cells ensure that developing T cells don’t react to proteins found in other body systems/organs?

A

AIRE (AutoImmune REgulator) transcription regulator turns on expression of tissue-specific proteins/ antigens (TRAs) from all over the body in the thymus, so immature T cells are exposed to them

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

it is more common for MHC [I/II] genes to be associated with autoimmune disease

A

more autoimmune diseases are associated with specific MHC II alleles, because most autoimmune diseases are driven by antibodies, and CD4+ T cells are required to induce B cell class switching

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

citrullination and its relevance to autoimmunity

A

arginine is modified to have an oxygen, which makes it become citrulline (via PAD/ peptidyl-arginine-deiminase)

citrullinated proteins are recognized by HLA

*note that PAD is upregulated by cigarette smoking

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

T/F: most human autoimmune diseases are polygenic

A

TRUE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

how does molecular mimicry play a role (potentially) in rheumatic fever? (hint - requires a specific infection)

A

molecular mimicry: autoimmune response triggered by an antigen that looks like self antigen

group A streptococcal M protein is similar to antigen found in cardiac muscle —> rheumatic fever

(potentially - no definitive evidence yet)

17
Q

by-stander immune activation

A

infection induces an environment that promotes lymphocyte activation

a DC carrying a pathogen, but also expressing its own antigens, may by chance run into a self-reactive T cell and induce autoimmunity

[remember that autoimmune diseases are often associated with/triggered by infection]

18
Q

2 types of drug-induced autoimmunity (DIA)

A
  1. immunological response (majority of cases) - drug hypersensitivity, usually reversible on drug withdrawal
  2. true autoimmune process - requires immunosuppressive treatment, progresses independently of drug withdrawal
19
Q

2 factors that contribute to chronic nature of autoimmune diseases

A
  1. immune system has amplification mechanisms to proliferate “useful” cells for combatting infection (in autoimmunity, though, these are self-reactive cells)
  2. epitope spreading: immune response starts with one antigen but quickly spreads to others

*both of these processes lead to increased number of self-reactive clones

20
Q

epitope spreading

A

immune response starts with one antigen but quickly spreads to others

21
Q

2 major patterns of autoimmune diseases

A
  1. organ-specific (ex- Type 1 diabetes, Hashimoto’s thyroiditis, Graves’ disease, Addison’s disease)
  2. systemic (ex - Rheumatoid arthritis, systemic lupus erythematosus, scleroderma)
22
Q

what organs are affected in the following organ-specific autoimmune diseases?
a. Type 1 diabetes
b. Hashimoto’s
c. Graves’
d. Addison’s

A

a. Type I diabetes - pancreas (insulin, beta cells)
b. Hashimoto’s - thyroid
c. Graves’ - thyroid (autoantibodies activate thyrotropin receptor)
d. Addison’s - adrenal

23
Q

Rheumatoid arthritis, systemic lupus erythematosus, and scleroderma are common in that they are all examples of _____ autoimmune disease

24
Q

what occurs in SLE and what are the treatment strategies that currently exist?

A

SLE = systemic lupus erythematosus

immune complex mediated systemic autoimmune disease —> too much Type I IFN production leads to high-level anti-nuclear IgG production

treatment:
- anti-IFNa antibody (Type I IFN) - Sifalimumab
- TLR inhibition
- B cell deletion (Rituximab)
- anti-BAFF anitbody (Tabalumab)

25
Sifalimumab, Rituximab, and Tabalumab are all used in treatment against SLE what do they do (note they can also be indicated for treatment of other diseases)
remember that SLE is due to too much Type I IFN that leads to high levels of anti-nuclear IgG (systemic autoimmune disease) Sifalimumab: anti-IFNa (Type I IFN) antibody Rituximab: B cell depletion (also used in treatment for non Hodgkin lymphoma) Tabalumab: anti-BAFF antibody
26
what occurs in rheumatoid arthritis
citrillination (altered arginine) of self protein leads to T and B cell response to self antigens in joint tissues —> synoviocyte activation, cytokine production, inflammation —> destruction of cartilage and bone
27
what are current treatments for rheumatoid arthritis?
remember that rheumatoid arthritis is destruction of cartilage and bone due to T/B cells recognizing citrullinated arginines in self-antigens - TNF inhibitors, anti-TNF antibodies (*Etanercept, Infliximab, Adalimumab, Golimumab, Centolizumab*) - IL-1 antagonist (*Anakinra*) - anti-IL-6 receptor antibody (*Tocilizumab*) - CTLA-4 fusion protein (binds B7, prevents it binding to CD28) - anti IL-17 antibodies (*Secukinumab*) - B cell deletion (*Rituximab*)